| Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity CR Moderbacher, SI Ramirez, JM Dan, A Grifoni, KM Hastie, D Weiskopf, ... Cell 183 (4), 996-1012. e19, 2020 | 1958 | 2020 |
| SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract YJ Hou, K Okuda, CE Edwards, DR Martinez, T Asakura, KH Dinnon, ... Cell 182 (2), 429-446. e14, 2020 | 1618 | 2020 |
| SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo YJ Hou, S Chiba, P Halfmann, C Ehre, M Kuroda, KH Dinnon III, SR Leist, ... Science 370 (6523), 1464-1468, 2020 | 1019 | 2020 |
| The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients L Premkumar, B Segovia-Chumbez, R Jadi, DR Martinez, R Raut, ... Science immunology 5 (48), eabc8413, 2020 | 962 | 2020 |
| A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice SR Leist, KH Dinnon, A Schäfer, VT Longping, K Okuda, YJ Hou, A West, ... Cell 183 (4), 1070-1085. e12, 2020 | 599 | 2020 |
| Broad neutralization of SARS-related viruses by human monoclonal antibodies AZ Wec, D Wrapp, AS Herbert, DP Maurer, D Haslwanter, M Sakharkar, ... Science 369 (6504), 731-736, 2020 | 595 | 2020 |
| Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 AC Walls, B Fiala, A Schäfer, S Wrenn, MN Pham, M Murphy, ... Cell 183 (5), 1367-1382. e17, 2020 | 526 | 2020 |
| In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies D Li, RJ Edwards, K Manne, DR Martinez, A Schäfer, SM Alam, K Wiehe, ... Cell 184 (16), 4203-4219. e32, 2021 | 346* | 2021 |
| Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody CG Rappazzo, LV Tse, CI Kaku, D Wrapp, M Sakharkar, D Huang, ... Science 371 (6531), 823-829, 2021 | 334 | 2021 |
| β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells S Zhou, CS Hill, S Sarkar, LV Tse, BMD Woodburn, RF Schinazi, ... The Journal of infectious diseases 224 (3), 415-419, 2021 | 333 | 2021 |
| Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses KO Saunders, E Lee, R Parks, DR Martinez, D Li, H Chen, RJ Edwards, ... Nature 594 (7864), 553-559, 2021 | 263 | 2021 |
| Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion LV Tse, KA Klinc, VJ Madigan, RM Castellanos Rivera, LF Wells, ... Proceedings of the National Academy of Sciences 114 (24), E4812-E4821, 2017 | 247 | 2017 |
| Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery NF Nidetz, MC McGee, VT Longping, C Li, L Cong, Y Li, W Huang Pharmacology & therapeutics 207, 107453, 2020 | 160 | 2020 |
| Modifications to the hemagglutinin cleavage site control the virulence of a neurotropic H1N1 influenza virus X Sun, LV Tse, AD Ferguson, GR Whittaker Journal of virology 84 (17), 8683-8690, 2010 | 145 | 2010 |
| Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease P Zhou, G Song, H Liu, M Yuan, W He, N Beutler, X Zhu, VT Longping, ... Immunity 56 (3), 669-686. e7, 2023 | 111* | 2023 |
| The current and future state of vaccines, antivirals and gene therapies against emerging coronaviruses LV Tse, RM Meganck, RL Graham, RS Baric Frontiers in microbiology 11, 658, 2020 | 110 | 2020 |
| A novel activation mechanism of avian influenza virus H9N2 by furin LV Tse, AM Hamilton, T Friling, GR Whittaker Journal of virology 88 (3), 1673-1683, 2014 | 88 | 2014 |
| Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays AM Sholukh, A Fiore-Gartland, ES Ford, MD Miner, YJ Hou, LV Tse, ... Journal of Clinical Microbiology 59 (10), 10.1128/jcm. 00527-21, 2021 | 87 | 2021 |
| Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms AC Puhl, EJ Fritch, TR Lane, LV Tse, BL Yount, CQ Sacramento, ... ACS omega 6 (11), 7454-7468, 2021 | 74 | 2021 |
| Strategies to circumvent humoral immunity to adeno-associated viral vectors LV Tse, S Moller-Tank, A Asokan Expert opinion on biological therapy 15 (6), 845-855, 2015 | 62 | 2015 |
Yixuan J. HouModerna TherapeuticsPatvirtintas el. paštas modernatx.com
